Etanercept-Induced Systemic Lupus Erythematosus in a Patient with Rheumatoid Arthritis by Kang, Min-Jung et al.
INTRODUCTION
Etanercept is a soluble tumor necrosis factor (TNF ) recep-
tor fusion protein, which inhibits the biological activity of
TNF . Specific therapy targeting TNF has been offered
an important advance in the treatment of active rheumatoid
arthritis (RA) (1). Although anti-inflammatory and disease-
modifying effect of anti-TNF therapy are well known, there
are concerns for development of serious side effects such as
autoimmune disorder, infection and neoplasm as the physi-
ologic actions of TNF are blocked (2, 3).
Drug-induced lupus was firstly reported by Hoffman in
1945, in a patient who developed hypersensitivity syndrome
similar to acute systemic lupus erythematosus (SLE) after
taking sulfadiazine (4). Up to 80 kinds of drugs have been
known to induce lupus-like syndrome, composing approxi-
mately 10% of the all SLE cases (5). Anti-TNF agents in-
cluding etanercept have recently been considered as drugs that
can potentially induce lupus, since new autoantibodies such
as antinuclear antibodies (ANAs) and anti-double stranded
DNA (anti-dsDNA) antibodies were detected in anti-TNF
treated patients (6-8).
Shakoor et al. described the first SLE case among the RA
patients treated with etanercept in 2002 (9). Since then, a
few similar cases have been reported, that alarmed the clini-
cians for development of SLE in RA patients treated with
anti-TNF agents (10-13). However, all of the reported cases
of anti-TNF -induced SLE was manifested without major
organ involvement and resolved shortly after the discontin-
uation of the therapy. Although a case of tuberculous pleurisy
following infliximab therapy was reported in Korea, etaner-
cept associated SLE was not reported previously (14). Here-
in, we describe a 55-yr-old Korean woman who developed
overt life threatening SLE complicated by pneumonia and
tuberculosis following etanercept treatment for RA.
CASE REPORT
A 55-yr-old Korean woman presented with fever and gen-
eralized weakness which persisted for 3 months. She had no
history of pulmonary tuberculosis or diabetes mellitus. She
was diagnosed as seropositive RA 20 yr ago, and had been
treated with prednisolone, NSAIDs and methotrexate. Since
she had continued active joint inflammation, 25 mg of etaner-
cept twice weekly subcutaneous injection was added to the
treatment 8 months ago. Despite improvement of her arthritic
symptoms, she began to experience severe fatigue and malaise
3 months ago. Intermittent high fever, myalgia, oral ulcers,
gum bleeding, and 10 kg-weight loss were associated. Phys-
ical examination revealed cachexic, chronic ill looking woman
with severe wasting. Her blood pressure was 130/75 mmHg,
heart rate 88/min, and body temperature 38.1℃. Her hands
demonstrated typical changes of RA with ulnar deviation
and deformity of her fingers. Conjunctiva was anemic. Shal-
low irregular shaped ulcers with hemorrhagic spots were noted
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Tumor necrosis factor (TNF) is known to play a critical role in the pathogenesis of
rheumatoid arthritis (RA). Etanercept is a recombinant soluble fusion protein of TNF
type II receptor and IgG, which acts as a specific TNF- antagonist. Anti-TNF-
therapy has been an important advance in the treatment of RA. However, induc-
tion of autoantibodies in some proportion of patients treated with TNF inhibitors
raised concerns for development of systemic autoimmune diseases such as sys-
temic lupus erythematosus (SLE). Although new autoantibody formation is com-
mon with anti-TNF therapy, there are only rare reports of overt SLE, most of which
manifested without major organ involvement and resolved shortly after discontinu-
ation of the therapy. We describe a 55-yr-old Korean woman who developed overt
life threatening SLE complicated by pneumonia and tuberculosis following etaner-
cept treatment for RA. This case is to our knowledge, the first report of etanercept-
induced SLE in Korea.
Key Words : Lupus Erythematosus, Systemic; Etanercept; TNFR-Fc fusion protein; Arthritis, Rheumatoid
Received : 11 April 2005
Accepted : 16 August 2005Etanercept-induced SLE 947
in the oral cavity. On chest examination, crackles were heard
over both lung fields. There was no abnormal finding with-
out hepatosplenomegaly in the abdomen. Initial complete
blood count revealed hemoglobin of 7.7 g/dL, white cell count
of 3,000/ L (65% neutrophil, 26% lymphocyte), and platelet
of 40,000/ L. Peripheral blood smear showed no abnormal
hematologic cells. Erythrocyte sedimentation rate was 11 mm/
hr and C-reactive protein was positive at 0.6 mg/dL (normal
<0.3). Blood chemistry values revealed a total protein of 6.6
g/dL, albumin of 2.4 g/dL, BUN 17 mg/dL, creatinine 0.6
mg/dL, AST 447 IU/L, and ALT 113 IU/L. Creatine kinase
was elevated to 253 IU/L. Urinalysis revealed one positive for
protein. ANA was positive at a titer of 1:640, staining speck-
led pattern, and rheumatoid factor was positive at 2,180 IU/
mL (normal <15 IU/mL). Anti-dsDNA was positive at 14.2
IU/mL (normal <10 IU/mL). Antibodies against ribonucle-
oprotein and Ro/SS-A were positive, but La/SS-B and Smith
were negative. C3 was 19.2 mg/dL, C4 was 9.9 mg/dL. Sym-
metrically narrowed joint spaces, bony erosion, and osteope-
nia were shown in hand radiography suggesting chronic RA
with destructive change. Chest radiography revealed pneu-
monia and pulmonary edema in both lung field (Fig. 1). Chest
CT showed pneumonia, pulmonary edema, and pleural effu-
sion with pulmonary hemorrhage suggestive of lupus pneu-
monitis (Fig. 2). Bone marrow examination was normal except
for increased megakaryocyte without evidence of hematologic
malignancies. 
A diagnosis of SLE with major organ involvement with
pneumonitis and thrombocytopenia was made. Etanercept
was discontinued and high dose corticosteroid was started.
Lupus pneumonitis complicated with pulmonary hemorrhage
was improved with corticosteroids treatment. However, resi-
dual lung infiltration remained. Bronchoscopic cell culture
and PCR of sputum revealed coexistent adenoviral infection,
and acyclovir was instituted. Two month later, her general
condition markedly improved. However, she was complicated
by unilateral pleural effusion, which showed positive for acid-
fast bacilli PCR. Anti-tuberculous therapy of isoniazid, etham-
butol, rifampin, and pyrazinamide was started. She is main-
tained on prednisolone 20 mg/day, hydroxychloroquine 300
mg/day, and nabumetone 1 g/day with minimal symptoms
upon 12 months of follow up. However, she still had high
titers of ANA and anti-dsDNA antibodies.
DISCUSSION
TNF is an important pro-inflammatory cytokine that can
cause inflammation and bony erosion in RA. TNF inhibi-
tors, such as infliximab, etanercept, and adalimumab were
shown to be very effective in reducing synovial inflammation
and retarding structural damage in RA patients. Anti-TNF
therapy has opened a new era in treatment of RA, and is being
used more and more in current rheumatologic practice. Al-
though TNF inhibitors are effective therapy for RA, the con-
cerns for serious side effects have been also raised. Adverse
events that can potentially occur in anti-TNF treated patients
include tuberculosis, bacterial sepsis, heart failure, hemato-
logic malignancy, and systemic autoimmune disease such as
SLE and systemic sclerosis (15).
Autoantibody formation was reported at high frequency
in anti-TNF treated patients. In RA patients treated with
Fig. 1. Chest radiography shows pneumonic consolidation and
pulmonary edema in both lung fields
Fig. 2. Chest CT shows pneumonic consolidation, pulmonary
edema, and pleural effusion or possible pulmonary hemorrhage.
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infliximab, ANA developed in 29-76.7% and anti-dsDNA
in 10-29% (7, 8, 16, 17). Also in etanercept treated RA pati-
ents, 11-36.3% patients had developed ANA, and 5-15%
developed anti-dsDNA (16, 18, 19). In Crohn’s disease, auto-
antibody development and infliximab-induced SLE were
reported (20-24). Shakoor et al. first reported four cases of etan-
ercept-induced SLE in a series of RA patients in 2002 (9).
Swale et al. also reported a case of SLE following 12 months
of etanercept therapy in the following year (10). In the pre-
vious reports, timing of the onset and offset of the SLE fea-
tures strongly supported a drug related effect of etanercept.
In these patients, SLE developed after mean 7.7 months (range
3-24) of commencing etanercept therapy, and were all women.
Most common clinical feature of SLE was skin rash. There
was no significant life threatening organ involvement such
as kidney, lung, heart and central nervous system. The SLE
features were resolved rapidly on stopping the treatment. The
British Society for Rheumatology recommends stopping anti-
TNF therapy and appropriate treatment if symptoms of
an SLE-like syndrome develop on anti-TNF treatment (25).
The pathogenesis of anti-TNF in development of SLE has
not been yet clarified. Cairns et al. explained that TNF may
up-regulate the cellular expression of the adhesion molecule
CD44, which has a role in the clearance of apoptotic neutro-
phil by phagocyte. Reduced CD44 expression by anti-TNF
can potentially induce SLE by abnormal clearance and expo-
sure to apoptotic materials (12, 26). Long term exposure over
30 weeks to infliximab has been suggested as a factor that can
lead to SLE in one study (17). Although autoantibody forma-
tion is quite prevalent in anti-TNF treated patients, overt
clinical syndrome of SLE is rare, suggesting development of
SLE in patients treated with anti-TNF have certain genetic
or environmental factors predisposing for systemic autoim-
mune diseases. 
As in our case, severe life-threatening SLE with major organ
involvement can occur after etanercept therapy. Risk factors
for development of systemic autoimmune diseases should
also be evaluated before starting anti-TNF therapy, as screen-
ing for tuberculosis recommended before anti-TNF treat-
ment.
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